Why Did Tyra Biosciences Plunge 15.3%?

On April 4, 2025, Tyra Biosciences experienced a significant drop of 15.3% in pre-market trading, reflecting a notable shift in investor sentiment towards the biotechnology company.

HC Wainwright recently revised its earnings per share (EPS) estimates for Tyra Biosciences, projecting a loss of $0.56 per share for the first quarter of 2025, down from the previous forecast of $0.53. This adjustment comes after the company reported earnings of $0.43 per share for the previous quarter, surpassing analysts' expectations of $0.48. The firm maintains a "Buy" rating and a $30.00 price target for Tyra Biosciences.

Several other research analysts have also weighed in on Tyra Biosciences. Wedbush reiterated an "outperform" rating with a $30.00 price target, while UBS Group initiated coverage with a "buy" rating and a $28.00 target price. The consensus rating among analysts is "Buy," with an average price target of $30.83.

Institutional investors have been active in adjusting their positions in Tyra Biosciences. Rhumbline Advisers increased its holdings by 4.1%, while Bank of New York Mellon Corp raised its stake by 5.2%. Wells Fargo & Company MN lifted its holdings by 51.7%, and US Bancorp DE acquired a new stake in the company. Institutional investors and hedge funds collectively own 84.14% of the stock.

Insider trading activity has also been noted, with Director Nina S. Kjellson selling 5,401 shares at an average price of $13.76. This transaction, along with other insider sales, has reduced their ownership by 1.20%. Insiders collectively own 15.40% of the company's stock.